By Fineline Cube 
Accurate Biotechnology, a Guangzhou-based biotech focused on organoid technology, reportedly raised RMB 100 million (USD 13.8 million) in a Series B financing round. The funding was co-led by Guangdong Technology Financial Fund of Funds and Toposcend Capital. The proceeds will be used to facilitate Accurate Bio’s research and development, translation, and global business layout of organoid technology.
Accurate Bio’s Ecosystem Platform
Accurate Bio boasts an integrated ecosystem platform covering the entire lifecycle of organoids. The company focuses on the large-scale application of organoid tumor treatment, regenerative medicine, and synthetic biology. This comprehensive approach positions Accurate Bio at the forefront of organoid technology, with the potential to transform multiple areas of medical research and treatment.-Fineline Info & Tech